Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 19 peer-reviewed journal articles Updated
Cardiology · Non-ST-Elevation Acute Coronary Syndrome

Standard Treatment: Medications and Procedures

At a Glance

NSTE-ACS treatment combines aspirin and other clot-preventing medicines with a high-intensity statin, followed by angiography to choose between a stent and bypass surgery. The decision depends on coronary anatomy, kidney function, bleeding risk, diabetes, and overall health.

Treating Type 1 NSTE-ACS is generally a two-step process: first, the medical team uses medications to stabilize any blood clots and prevent new ones; second, they decide on a procedure to physically restore blood flow to your heart muscle [1][2]. This combined approach, guided by your specific risk level, is the standard of care for modern heart treatment.

The Medication Regimen: Antithrombotic Therapy

When you are admitted, your doctors will usually start several medications designed to reduce inflammation in your arteries and prevent a partial blockage from becoming total [1]. Note that choices depend heavily on your diagnostic certainty, kidney function, and bleeding risk.

  • Antiplatelet Therapy: This is the backbone of treatment. You will usually receive Aspirin immediately [1]. Unless contraindicated, you will also likely be prescribed a second antiplatelet drug called a P2Y12 inhibitor, such as ticagrelor, prasugrel, or clopidogrel [3][4]. (For example, prasugrel is contraindicated if you have a history of stroke or TIA).
  • Anticoagulants: Unlike the antiplatelet pills mentioned above, these are typically given as an injection or IV (like heparin) while you are in the hospital. They provide immediate protection against new clots [1].
  • High-Intensity Statins: You will likely start a high dose of a cholesterol-lowering medication (like atorvastatin or rosuvastatin). In ACS, these drugs do more than lower cholesterol—they help stabilize the plaques in your arteries [1][5].

The “Pretreatment” Discussion

In the past, doctors gave the second antiplatelet pill as soon as a patient walked through the door. However, current guidelines (such as the 2023 ESC update) now recommend against routine “pretreatment” for particular NSTE-ACS patients proceeding to early angiography with unknown coronary anatomy [6][7].

Waiting until the angiogram is performed allows doctors to see if you need stents or surgery. Giving these drugs too early can increase the risk of serious bleeding and may delay a necessary bypass surgery by several days while the drug wears off [8][7]. Do not delay or withhold prescribed medications yourself; the treating team will balance your bleeding and ischemic risks.

Procedures: Restoring the Flow

Once your medical team has a “map” of your heart from the angiogram, they must decide on the best way to bypass or open the blockages. This decision often involves a Heart Team—a collaborative group including interventional cardiologists (who do stents) and cardiac surgeons (who do bypass) [9][10].

1. Percutaneous Coronary Intervention (PCI)

A cardiologist inserts a thin tube into an artery (usually in the wrist or groin) and uses a small balloon to open the blockage, then places a stent (a tiny mesh tube) to keep it open [11].

  • Benefits: Less invasive, faster physical recovery (often home in a few days).
  • Risks and Cons: Complications include bleeding, contrast-associated kidney injury, stroke, stent thrombosis, or the chance of needing a repeat procedure in the future [12][13].

2. Coronary Artery Bypass Grafting (CABG)

This is traditional open-heart surgery. A surgeon takes a healthy blood vessel from another part of your body (like your chest or leg) and uses it to “bypass” the blocked artery [11].

  • Benefits: Often more durable (lasts longer) and more comprehensive for patients with many blockages or diabetes [14][13].
  • Risks and Cons: More invasive, requires a longer hospital stay, risks of infection and stroke, and a recovery period of several weeks [12][10].

How the Decision is Made

The Heart Team doesn’t just guess; they use your medical history and the “complexity” of your blockages to decide [15]. You are more likely to be recommended for CABG (Bypass) if you have:

  • Diabetes: Surgery often has better long-term outcomes for diabetic patients with multiple blockages [13][12].
  • Left Main Disease: A blockage in the main artery supplying the left side of the heart often favors surgery [16].
  • Complex Anatomy: If you have many blockages in difficult-to-reach places, a surgeon can often provide a more complete fix [17][10].

Regardless of the procedure, your long-term health will depend on adhering to your specific medication plan [18][19].

Common questions in this guide

What medicines are commonly used first for NSTE-ACS?
Treatment commonly includes aspirin, a second antiplatelet medicine such as ticagrelor, prasugrel, or clopidogrel, and an anticoagulant such as heparin while you are in the hospital. A high-intensity statin is also usually started, but the exact plan depends on your diagnosis, kidney function, bleeding risk, and other health factors.
Why might doctors wait to give the second antiplatelet medicine until after an angiogram?
For some people going to early angiography, doctors wait until they can see the coronary anatomy before giving the second antiplatelet medicine. Giving it too early can increase bleeding and may delay bypass surgery if surgery is needed.
Are stents or bypass surgery better for NSTE-ACS?
Neither procedure is best for everyone. A stent procedure is less invasive and usually allows a faster recovery, while bypass surgery may provide a more durable or complete result when there are multiple or complex blockages, left main disease, or diabetes.
Who decides whether I need a stent or bypass surgery?
A Heart Team may review your case, including an interventional cardiologist and a cardiac surgeon. The team considers your coronary anatomy, the number and complexity of blockages, diabetes, bleeding risk, kidney function, and overall health.
How long will I need dual antiplatelet therapy after NSTE-ACS?
The duration varies according to your bleeding risk, risk of another clot, and whether you received a stent or bypass surgery. Your cardiologist will provide the specific schedule, and you should not stop either antiplatelet medicine without discussing it with the treating team.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Which P2Y12 inhibitor (ticagrelor, prasugrel, or clopidogrel) am I receiving, and what was the reason for choosing that specific one?
  2. 2.Why is the team waiting until after my angiogram to give me the second antiplatelet pill?
  3. 3.If I have complex blockages, will a 'Heart Team' (including both a cardiologist and a surgeon) review my case to decide between stents and bypass?
  4. 4.Based on my heart's anatomy, what are the long-term pros and cons of PCI (stents) versus CABG (bypass surgery) for me?
  5. 5.How long will I need to be on 'Dual Antiplatelet Therapy' (DAPT) after I leave the hospital, and how does it differ if I have a stent versus bypass?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (19)
  1. 1

    2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

    Rao SV, O'Donoghue ML, Ruel M, et al.

    Circulation 2025; (151(13)):e771-e862 doi:10.1161/CIR.0000000000001309.

    PMID: 40014670
  2. 2

    2018 Guidelines of the Taiwan Society of Cardiology, Taiwan Society of Emergency Medicine and Taiwan Society of Cardiovascular Interventions for the management of non ST-segment elevation acute coronary syndrome.

    Li YH, Wang YC, Wang YC, et al.

    Journal of the Formosan Medical Association = Taiwan yi zhi 2018; (117(9)):766-790 doi:10.1016/j.jfma.2018.06.002.

    PMID: 30017533
  3. 3

    Antithrombotic PreTreatment and Invasive Strategies in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome.

    Camaro C, Damman P

    Journal of clinical medicine 2020; (9(8)) doi:10.3390/jcm9082578.

    PMID: 32784868
  4. 4

    Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial.

    Gimbel M, Qaderdan K, Willemsen L, et al.

    Lancet (London, England) 2020; (395(10233)):1374-1381 doi:10.1016/S0140-6736(20)30325-1.

    PMID: 32334703
  5. 5

    Effects of lowest-dose vs. highest-dose pitavastatin on coronary neointimal hyperplasia at 12-month follow-up in type 2 diabetic patients with non-ST elevation acute coronary syndrome: an optical coherence tomography analysis.

    Lim JW, Jeong HS, Hong SJ, et al.

    Heart and vessels 2019; (34(1)):62-73 doi:10.1007/s00380-018-1227-0.

    PMID: 30047013
  6. 6

    Real-world adoption of the 2023 European Society of Cardiology guidelines regarding antiplatelet strategies in acute coronary syndromes: Insights from the European READAPT-2 survey.

    Angiolillo DJ, Erlinge D, Gale CP, et al.

    International journal of cardiology 2026; (453()):134288 doi:10.1016/j.ijcard.2026.134288.

    PMID: 41819190
  7. 7

    Assessment of Pretreatment With Oral P2Y12 Inhibitors and Cardiovascular and Bleeding Outcomes in Patients With Non-ST Elevation Acute Coronary Syndromes: A Systematic Review and Meta-analysis.

    Dawson LP, Chen D, Dagan M, et al.

    JAMA network open 2021; (4(11)):e2134322 doi:10.1001/jamanetworkopen.2021.34322.

    PMID: 34797371
  8. 8

    Precatheterization Use of P2Y12 Inhibitors in Non-ST-Elevation Myocardial Infarction Patients Undergoing Early Cardiac Catheterization and In-Hospital Coronary Artery Bypass Grafting: Insights From the National Cardiovascular Data Registry®.

    Badri M, Abdelbaky A, Li S, et al.

    Journal of the American Heart Association 2017; (6(9)) doi:10.1161/JAHA.117.006508.

    PMID: 28939715
  9. 9

    Non-ST-segment elevation acute coronary syndrome: understanding the full spectrum to guide management.

    Savonitto S, Alpert JS, Thiele H, et al.

    European heart journal 2025; doi:10.1093/eurheartj/ehaf958.

    PMID: 41358986
  10. 10

    Percutaneous coronary intervention versus coronary artery bypass in treatment of non-ST-segment elevation acute syndromes: a systematic review and meta-analysis study.

    Khalifehsoltani A, Oghenemaro EF, Zwamel AH, et al.

    European journal of translational myology 2025; (35(1)) doi:10.4081/ejtm.2024.12930.

    PMID: 39606919
  11. 11

    Application of the fourth universal definition of myocardial infarction in clinical practice.

    Mair J, Cullen L, Giannitsis E, et al.

    Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals 2020; (25(4)):322-330 doi:10.1080/1354750X.2020.1764108.

    PMID: 32362195
  12. 12

    Revascularization strategies in Non-ST segment elevation myocardial infarction: the clash continues.

    Zuccarelli V, Giunti F, Chiarito M, et al.

    Frontiers in cardiovascular medicine 2025; (12()):1614843 doi:10.3389/fcvm.2025.1614843.

    PMID: 40910145
  13. 13

    Comparison of Outcome of Coronary Artery Bypass Grafting Versus Drug-Eluting Stent Implantation for Non-ST-Elevation Acute Coronary Syndrome.

    Chang M, Lee CW, Ahn JM, et al.

    The American journal of cardiology 2017; (120(3)):380-386 doi:10.1016/j.amjcard.2017.04.038.

    PMID: 28595861
  14. 14

    Meta-analysis Comparing Percutaneous Coronary Intervention With Coronary Artery Bypass Grafting for Non-ST Elevation Acute Coronary Syndrome in Patients With Multivessel or Left Main Disease.

    Barssoum K, Kumar A, Rai D, et al.

    Current problems in cardiology 2022; (47(10)):101306 doi:10.1016/j.cpcardiol.2022.101306.

    PMID: 35810843
  15. 15

    Latest evidence on assessment and invasive management of non-ST-segment elevation acute coronary syndrome (NSTE-ACS) in the older population.

    Gill K, Mills GB, Wang W, et al.

    Expert review of cardiovascular therapy 2025; (23(3)):73-86 doi:10.1080/14779072.2025.2476125.

    PMID: 40056095
  16. 16

    Percutaneous vs. surgical revascularization of non-ST-segment elevation myocardial infarction with multivessel disease: the SWEDEHEART registry.

    Omerovic E, Råmunddal T, Petursson P, et al.

    European heart journal 2025; (46(6)):518-531 doi:10.1093/eurheartj/ehae700.

    PMID: 39601339
  17. 17

    Coronary Artery Bypass Grafting Versus Percutaneous Coronary Intervention in Patients With Non-ST-Elevation Myocardial Infarction and Left Main or Multivessel Coronary Disease.

    Freitas P, Madeira M, Raposo L, et al.

    The American journal of cardiology 2019; (123(5)):717-724 doi:10.1016/j.amjcard.2018.11.052.

    PMID: 30558758
  18. 18

    Treatment practices and lipid profile of patients with acute coronary syndrome: results from a tertiary care hospital.

    Farmakis I, Zafeiropoulos S, Kartas A, et al.

    Acta cardiologica 2020; (75(6)):527-534 doi:10.1080/00015385.2019.1626087.

    PMID: 31219734
  19. 19

    Revascularization for Coronary Artery Disease: Principle and Challenges.

    Gu D, Qu J, Zhang H, Zheng Z

    Advances in experimental medicine and biology 2020; (1177()):75-100 doi:10.1007/978-981-15-2517-9_3.

    PMID: 32246444

This page explains NSTE-ACS medications and procedures for informational purposes only and does not constitute medical advice. Your cardiology team must choose treatment based on your coronary anatomy, kidney function, bleeding risk, and overall health.

Get notified when new evidence is published on intermediate coronary syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.